Dr. Na Young Kim, Ph.D, brings over 15 years of experience in drug development, specializing in virology. She earned her bachelor’s degree from Sogang University and completed her master’s and doctoral degrees in life sciences at the same institution. Throughout her academic journey, Dr. Kim focused on developing cell lines for glycoprotein drug production and conducted research on protein drug production using viruses.

Dedicated to advancing gene vaccine development for infectious diseases, Dr. Kim has been involved in numerous national projects and has published over 16 papers as a lead author, showcasing her commitment to scientific progress.

Since 2019, Dr. Kim has served as the Head of ABION Research Center, leading research initiatives on multiple anti-cancer drug pipelines. She has also contributed to the development of various drug types, including protein and antibody therapeutics, vaccines, and gene therapeutics targeting infectious diseases. Additionally, Dr. Kim advises several government organizations, including the Korean Ministry of Food and Drug Safety.

Recognized for her expertise, Dr. Kim was appointed as the Head of ABION Development Division Department in 2023. In this role, she leads the development efforts for ABN401, ABN501 anticancer drugs, and the innovative ABN101 inhaled universal antiviral.

Dr. Kim’s extensive experience and leadership make her a valuable asset to ABION’s mission of developing innovative therapeutic solutions.